omadacycline
Trade name: nuzyra
Approved
Oct 2, 2018
Omadacycline is a tetracyclin-derivative antibiotic, originated in Tufts University, and later co-developed by Merck and Paratek Pharmaceuticals. The drug was approved for treatment of community-acquired pneumonia, and for treatment of acute bacterial skin and skin structure infections. Omadacycline tosylate is available as tablets and in injectable form. — NCATS
Clinical trial activity
19 trials · 13 clinical orgs · 1 marketing orgs
Earliest trial started Jul 18, 2007 (NCT03716024)
Timeline
2000s
- Jan 1, 2007
Paratek Pharmaceuticals Inc — Earliest Phase 2 Sponsor(trial)
- Jan 1, 2009
Paratek Pharmaceuticals Inc — Earliest Phase 3 Sponsor(trial)
2010s
- Oct 2, 2018
Paratek Pharmaceuticals Inc — Earliest FDA Approval
- Oct 2, 2018
Paratek Pharmaceuticals Inc — NDA Secondary Org
- Oct 2, 2018
Paratek Pharmaceuticals Inc — NDA Organization
- Jan 1, 2019
Paratek Pharmaceuticals Inc — Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
- Bacterial Infections · Phase 3
- Bone Diseases, Infectious · Phase 2
- Community-Acquired Infections · Phase 3
- Cystic Fibrosis · Phase 4
- Cystitis · Phase 2
- Diabetes Mellitus · Phase 1
- Gastrointestinal Microbiome · Phase 4
- Healthy Volunteers · Phase 1
- Infections · Phase 2
- Mycobacterium Infections, Nontuberculous · Phase 2
- Pneumonia, Bacterial · Phase 3
- Pyelonephritis · Phase 2
- Respiratory Tract Infections · Phase 2
- Skin Diseases, Bacterial · Phase 2
- Skin Diseases, Infectious · Phase 3
- Soft Tissue Infections · Phase 3
- Urinary Tract Infections · Phase 2
- Wound Infection · Phase 1
Mechanism of action
- 30S ribosomal protein S12ANTAGONIST
rpsL antagonist
- Bacterial 70S ribosomeINHIBITOR
Bacterial 70S ribosome inhibitor
Inhibits bacterial protein synthesis.
Active against gram-positives expressing tetracycline resistance proteins tetK, tetL, tetM.
30S subunit
- 30S ribosomal protein S2 (rpsB) ↗
- 50S ribosomal protein L4 (rplD) ↗
- 30S ribosomal protein S15 (rpsO) ↗
- 30S ribosomal protein S16 (rpsP) ↗
- 30S ribosomal protein S17 (rpsQ) ↗
- 30S ribosomal protein S18 (rpsR) ↗
- 30S ribosomal protein S19 (rpsS) ↗
- 30S ribosomal protein S20 (rpsT) ↗
- 30S ribosomal protein S21 (rpsU) ↗
- 30S ribosomal protein S3 (rpsC) ↗
- 30S ribosomal protein S4 (rpsD) ↗
- 30S ribosomal protein S5 (rpsE) ↗
- 30S ribosomal protein S6 (rpsF) ↗
- 30S ribosomal protein S7 (rpsG) ↗
- 30S ribosomal protein S8 (rpsH) ↗
- 30S ribosomal protein S9 (rpsI) ↗
- 50S ribosomal protein L35 (rpmI) ↗
- 50S ribosomal protein L36 2 (ykgO) ↗
- 50S ribosomal protein L36 (rpmJ) ↗
- 50S ribosomal protein L3 (rplC) ↗
- 50S ribosomal protein L5 (rplE) ↗
- 50S ribosomal protein L6 (rplF) ↗
- 50S ribosomal protein L7/L12 (rplL) ↗
- 30S ribosomal protein S1 (rpsA) ↗
- 30S ribosomal protein S10 (rpsJ) ↗
- 30S ribosomal protein S11 (rpsK) ↗
- 30S ribosomal protein S12 (rpsL) ↗
- 30S ribosomal protein S13 (rpsM) ↗
- 30S ribosomal protein S14 (rpsN) ↗
- 50S ribosomal protein L10 (rplJ) ↗
- 50S ribosomal protein L11 (rplK) ↗
- 50S ribosomal protein L13 (rplM) ↗
- 50S ribosomal protein L14 (rplN) ↗
- 50S ribosomal protein L15 (rplO) ↗
- 50S ribosomal protein L16 (rplP) ↗
- 50S ribosomal protein L17 (rplQ) ↗
- 50S ribosomal protein L18 (rplR) ↗
- 50S ribosomal protein L19 (rplS) ↗
- 50S ribosomal protein L1 (rplA) ↗
- 50S ribosomal protein L20 (rplT) ↗
- 50S ribosomal protein L21 (rplU) ↗
- 50S ribosomal protein L22 (rplV) ↗
- 50S ribosomal protein L23 (rplW) ↗
- 50S ribosomal protein L24 (rplX) ↗
- 50S ribosomal protein L25 (rplY) ↗
- 50S ribosomal protein L27 (rpmA) ↗
- 50S ribosomal protein L28 (rpmB) ↗
- 50S ribosomal protein L29 (rpmC) ↗
- 50S ribosomal protein L2 (rplB) ↗
- 50S ribosomal protein L30 (rpmD) ↗
- 50S ribosomal protein L31 type B (ykgM) ↗
- 50S ribosomal protein L31 (rpmE) ↗
- 50S ribosomal protein L32 (rpmF) ↗
- 50S ribosomal protein L33 (rpmG) ↗
- 50S ribosomal protein L34 (rpmH) ↗
Approval history
- approvedPriority reviewFast trackOct 2, 2018
Chemistry & pharmacology
SMILES
CN(C)c1cc(CNCC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O- Mol. weight
- 556.66 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1689772 ↗
- WikipediaOmadacycline ↗
- NCATS090IP5RV8F ↗
- ChEMBLCHEMBL2103854 ↗
Also known as
- 7-dimethylamino-9-(2,2-dimethylpropyl)aminomethylcycline
- amadacyclin
- amadacycline
- amadacycline
- omadacycline
- omadacycline
- omadacycline
- omadacycline
- omadacycline tosylate
- omadacycline tosylate
- omadacycline tosylate
- ptk0796
- ptk 0796
- ptk 0796
- ptk 0796
- ptk-0796
- ptk-0796
- ptk-0796
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06462326 | Phase 1 | Apr 16, 2024 | Zai Lab Pty. Ltd., Zhejiang University |
| NCT06162286 | Phase 3 | Nov 17, 2023 | Fudan University, Zai Lab Pty. Ltd. |
| NCT05753215 | Phase 2 | May 9, 2023 | Paratek Pharmaceuticals Inc, University of California, Los Angeles |
| NCT05515562 | Phase 4 | Jan 31, 2023 | High Point University, Paratek Pharmaceuticals Inc, University of Houston, Wake Forest University |
| NCT05217537 | Phase 1 | Apr 6, 2022 | Paratek Pharmaceuticals Inc |
| NCT04922554 | Phase 2 | Oct 15, 2021 | Paratek Pharmaceuticals Inc |
| NCT04779242 | Phase 3 | Feb 25, 2021 | Paratek Pharmaceuticals Inc |
| NCT06030219 | Phase 1 | Oct 12, 2020 | Ohio State University, Paratek Pharmaceuticals Inc, University of Houston |
| NCT04460586 | Phase 4 | Sep 1, 2020 | Paratek Pharmaceuticals Inc, University of Southern California |
| NCT04144374 | Phase 1 | Dec 31, 2019 | Hartford Hospital, Paratek Pharmaceuticals Inc, University of Connecticut |
| NCT04160260 | Phase 1 | Nov 30, 2019 | Paratek Pharmaceuticals Inc |
| NCT03757234 | Phase 2 | Nov 19, 2018 | Paratek Pharmaceuticals Inc |
| NCT03425396 | Phase 2 | Dec 28, 2017 | Paratek Pharmaceuticals Inc |
| NCT02877927 | Phase 3 | Aug 1, 2016 | Paratek Pharmaceuticals Inc |
| NCT02531438 | Phase 3 | Nov 1, 2015 | Paratek Pharmaceuticals Inc |
| NCT02378480 | Phase 3 | Jun 1, 2015 | Paratek Pharmaceuticals Inc |
| NCT00876850 | Phase 3 | Jul 1, 2009 | Paratek Pharmaceuticals Inc |
| NCT00865280 | Phase 3 | Mar 1, 2009 | Novartis, Paratek Pharmaceuticals Inc |
| NCT03716024 | Phase 2 | Jul 18, 2007 | Paratek Pharmaceuticals Inc |
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Paratek Pharmaceuticals Inc | For profit | 17 | 12 | 4 | 2007 |
| University of Houston | Academic/Hospital | 2 | 1 | 2 | 2020 |
| Zai Lab Pty. Ltd. | For profit | 2 | 2 | 2 | 2023 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Hartford Hospital | Academic/Hospital | 1 | 0 | 1 | 2019 |
| High Point University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Novartis | For profit | 1 | 0 | 1 | 2009 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Connecticut | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Wake Forest University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2024 |
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Paratek Pharmaceuticals Inc | For profit | NDA2 | Oct 2, 2018 |
| Paratek Pharmaceuticals Inc | For profit | NDA | Oct 2, 2018 |